Helix Biopharma Corp.
HBP.TO
TSX
| 04/30/2026 | 01/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 47.22% | -49.33% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.30% | -24.82% | |||
| Operating Income | -0.30% | 24.82% | |||
| Income Before Tax | 4.14% | 29.57% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 4.14% | 29.57% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 4.14% | 29.57% | |||
| EBIT | -0.30% | 24.82% | |||
| EBITDA | -0.44% | 24.76% | |||
| EPS Basic | 4.48% | 30.21% | |||
| Normalized Basic EPS | 4.76% | 30.00% | |||
| EPS Diluted | 4.48% | 30.21% | |||
| Normalized Diluted EPS | 4.76% | 30.00% | |||
| Average Basic Shares Outstanding | 0.00% | 0.67% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.67% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||